Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on the development, manufacturing, and commercialization of pharmaceutical products for dermatological conditions, specifically photodynamic therapy (PDT) ¹. The company's primary products are Ameluz, a prescription drug, and the BF-RhodoLED and RhodoLED XL lamp series (collectively, "RhodoLED Lamps"), which are used together for PDT ². This treatment targets actinic keratosis (AK), a common pre-cancerous skin lesion ³. The company generates revenue by selling these products directly to dermatology offices and groups within the United States ⁴.

The core business model revolves around the Ameluz PDT therapy, which is a two-step process involving the application of a photosensitizer drug (Ameluz) and its activation by a selective light source (RhodoLED Lamps) to destroy fast-growing cells ⁵. This therapy is highly effective, with up to 91% clearance after one or two treatments and limited or no scarring ⁶. The company's revenue is primarily transactional, derived from direct sales of Ameluz and RhodoLED Lamps to dermatologists ⁷. While no single customer accounts for more than 10% of net revenues or accounts receivable ⁸, the company notes that many existing and potential customers are forming Group Purchasing Organizations (GPOs) to lower costs, which could impact pricing ⁹.

The company's main product, Ameluz, in combination with the RhodoLED Lamps, is approved for the lesion-directed and field-directed treatment of mild-to-moderate AK on the face and scalp ¹⁰. AK is the most common pre-cancer, affecting over 58 million Americans ¹¹. The market for AK treatments is estimated at roughly $4 billion ¹², with cryotherapy representing approximately 86% ¹³, topicals 12% ¹⁴, and PDT approximately 2% ¹⁵. Biofrontera's primary competitor in the PDT space is Levulan® and its associated light, Blu-U® ¹⁶. The company aims to expand its share in the PDT market and convert cryotherapy treatments for more than 14 lesions to Ameluz PDT, targeting an estimated 11% or $500 million of the total AK market ¹⁷.

For the fiscal year ended December 31, 2025, Biofrontera reported total net revenues of $41.705 million ¹⁸, an increase of $4.402 million or 11.8% from $37.303 million in 2024 ¹⁹. Cost of revenues, related party, decreased by $7.744 million, or 43.4%, to $10.111 million in 2025 from $17.855 million in 2024 ²⁰. Total operating expenses decreased by $1.478 million to $53.053 million in 2025 from $54.531 million in 2024 ²¹. The company reported a loss from operations of $(11.348) million in 2025, an improvement from $(17.210) million in 2024 ²². Net loss for 2025 was $(10.536) million, compared to $(17.759) million in 2024 ²³. Basic and diluted EPS improved to $(1.04) in 2025 from $(3.22) in 2024 ²⁴. As of December 31, 2025, cash and cash equivalents stood at $6.392 million ²⁵, total liabilities were $18.084 million ²⁶, and convertible notes payable were $4.589 million ²⁷. The accumulated deficit was $127.9 million ²⁸.

The year-over-year revenue increase was primarily driven by organic growth in Ameluz sales volume of $4.1 million and a $0.7 million increase due to a higher Ameluz unit price ²⁹. This was partially offset by a $0.3 million decline in RhodoLED Lamps sales following the initial surge from the BF-RhodoLED XL launch in 2024 ³⁰. The significant decrease in cost of revenues, related party, was due to a strategic transaction that reduced the cost of revenues per unit to approximately 5% from July 2025 onwards, compared to 25% to 50% previously ³¹. Additionally, $2.1 million of purchase price accrued under the old agreement was forgiven ³², though partially offset by $2.2 million in earnout payments under the new agreement ³³. Selling, general and administrative expenses increased by $4.0 million, primarily due to $6.6 million in higher external legal costs related to patent claims, partially offset by a $1.1 million reduction in direct sales personnel expenses due to decreased headcount, $1.0 million in sales support savings, a $0.4 million Xepi Prescription Drug User fee write-off, a $0.3 million decrease in intangible asset amortization, and a $0.2 million decrease in bad debt expense ³⁴. R&D expenses increased by $1.6 million due to the company assuming full control of Ameluz clinical trials in the U.S. for the entire year ³⁵.

During 2025, Biofrontera completed a Strategic Transaction on October 20, 2025, acquiring all U.S. rights to Ameluz and RhodoLED from the Biofrontera Group ³⁶. This transaction involved Biofrontera AG receiving 3,019 shares of Series D Convertible Preferred Stock ³⁷ and an earnout agreement where Biofrontera Inc. will pay 12% of U.S. Ameluz revenues up to $65.0 million and 15% on revenues exceeding $65.0 million, replacing a previous transfer pricing model ³⁸. This new structure is expected to reduce overall costs and accelerate the company's path to break-even ³⁹. On November 6, 2025, the company sold the intangible asset related to its Xepi product line for initial proceeds of $3 million, with potential for up to an additional $7 million in milestone payments ⁴⁰. In October 2024, the FDA approved an increase in the maximally approved dosage of Ameluz from one to three tubes per treatment ⁴¹. Also in October 2024, the company received Phase III trial results for Ameluz PDT as a treatment for superficial basal cell carcinoma (sBCC), showing 65.5% success in the composite endpoint compared to 4.8% with placebo ⁴². A Supplemental New Drug Application for sBCC was submitted to the FDA in November 2025, with a Prescription Drug User Fee Act date of September 28, 2026 ⁴³. A new formulation of Ameluz without propylene glycol, extending patent protection to 2043, was implemented in all U.S. productions since 2024 ⁴⁴.

Biofrontera's strategic objectives for the future include expanding U.S. sales of Ameluz in combination with RhodoLED Lamps for AK treatment, aiming to position Ameluz as the standard of care by acquiring new customers and growing therapy use among existing ones ⁴⁵. The company also plans to leverage potential future approvals and label extensions for Ameluz in the U.S. market, continuing its clinical development efforts after assuming responsibility for these trials since June 1, 2024 ⁴⁶. Furthermore, Biofrontera intends to strategically manage its portfolio by opportunistically adding complementary products or services through acquiring or licensing intellectual property to further leverage its commercial infrastructure and customer relationships ⁴⁷.

Regarding growth areas, the company is actively pursuing label expansion for Ameluz. A Supplemental New Drug Application (sNDA) for the treatment of superficial basal cell carcinoma (sBCC) was submitted to the FDA in November 2025, with a Prescription Drug User Fee Act date set for September 28, 2026 ⁴⁸. Clinical trial results for sBCC showed Ameluz-PDT achieved 65.5% success in the composite endpoint, significantly higher than 4.8% for placebo-PDT ⁴⁹. Additionally, the company is developing Ameluz for moderate to severe acne, with the last-patient-out of the treatment phase in Q3 2025, Phase 2 data obtained in Q1 2026, and the Clinical Study Report (CSR) for the treatment phase expected in Q3 2026 ⁵⁰. For actinic keratosis on the trunk and extremities, the last-patient-out of the treatment phase was in Q3 2025, with the CSR expected in Q2 2026 and a regulatory filing for sNDA anticipated in Q3 2026 ⁵¹. A pharmacokinetics study for AK on the trunk and extremities, applying three tubes of Ameluz, had its last-patient-out in Q4 2025, with the CSR expected in Q2 2026 and regulatory filing expected alongside the Phase 3 study in Q3 2026 ⁵². The company also plans to start enrollment for an AK Pain Reduction study in 2027 ⁵³. The FDA approval in October 2024 to increase the maximally approved dosage of Ameluz from one to three tubes per treatment, combined with the RhodoLED XL Lamp, is foundational to support the planned trunk and extremities label expansion ⁵⁴.

Operationally, the Strategic Transaction completed on October 20, 2025, is expected to reduce overall costs for the company and accelerate its timeframe to reach break-even ⁵⁵. This is primarily due to a transition from a transfer pricing model (25% to 50% of revenue) to an earnout model (12% of U.S. Ameluz revenues up to $65.0 million, 15% thereafter) for product costs, effective retroactively to June 1, 2025 ⁵⁶. The company has also assumed full control of the Ameluz New Drug Application and Investigational New Drug, enabling independent management of clinical development and full responsibility for manufacturing and marketing Ameluz and RhodoLED lamps in the U.S. ⁵⁷. In terms of supply chain, Biofrontera will temporarily rely on the Former Ameluz Licensor for manufacturing until securing necessary licenses and contracts ⁵⁸. An agreement for primary procurement of the active pharmaceutical ingredient (API) with Midas Pharma GmbH has been entered into, and a secondary API source has been identified ⁵⁹. Production of Ameluz is carried out by contract manufacturers Glaropharm AG in Switzerland and Pharbil Waltrop GmbH in Germany, with RhodoLED Lamps production transferring from the Former Ameluz Licensor to Discovery ⁶⁰.

Planned capital allocation includes continued R&D expenditures to improve RhodoLED Lamps capabilities and develop new products ⁶¹. The company has financed operations and capital expenditures through product sales, convertible notes, and equity financings ⁶². As of December 31, 2025, there were 1,200,101 shares available for future awards under the amended 2021 Omnibus Incentive Plan ⁶³. The company does not currently intend to pay any cash dividends on its common stock in the foreseeable future, anticipating retaining all future earnings for business operations ⁶⁴.

The company faces structural headwinds and execution risks, including the potential for generic versions of Ameluz to enter the market, which could significantly reduce prices and market share ⁶⁵. The success of Ameluz depends on factors such as successful completion of further clinical trials, receipt of additional regulatory approvals, maintaining regulatory compliance in manufacturing, sourcing sufficient raw materials, and expanding reimbursement coverage ⁶⁶. Geopolitical instability, trade disputes, and tariffs, particularly on European imports, could materially increase costs and disrupt the supply chain ⁶⁷. The company is also subject to extensive healthcare laws and regulations, and failure to comply could have a material adverse effect ⁶⁸. There is substantial doubt about the company's ability to continue as a going concern for at least one year from the report's issuance date, necessitating additional capital or financing until cash flow from operations is sufficient ⁶⁹.

Biofrontera faces several material risks, including the potential for generic versions of Ameluz to enter the market, which could lead to significant price reductions and loss of market share ⁷⁰. The company's business is substantially dependent on the success of Ameluz, and failure to obtain and maintain regulatory approvals or reimbursement for existing and additional indications could materially harm the business ⁷¹. Manufacturing failures or suboptimal performance of equipment, or non-compliance with cGMP or other regulations by the company or its partners, could disrupt operations, increase costs, impair product quality, and prevent or delay commercialization ⁷². Inadequate intellectual property protection could hinder effective competition ⁷³, and ongoing or future intellectual property lawsuits could be expensive, time-consuming, and unsuccessful ⁷⁴. International dealings expose the company to currency risks, which may adversely affect operating results and net income ⁷⁵. Competing products and future emerging therapies may erode sales ⁷⁶. Geopolitical instability, trade disputes, and tariffs on European imports could materially increase costs, disrupt the supply chain, and adversely affect financial condition ⁷⁷. Limited or unavailable insurance coverage and medical expense reimbursement for products, especially future indications, could make sales difficult ⁷⁸. Healthcare legislative changes, including government price setting and increased manufacturer liability under Medicare Part D, could adversely affect profitability ⁷⁹. Inability to maintain effective marketing and sales capabilities or establish relationships with Group Purchasing Organizations (GPOs) could limit revenue growth ⁸⁰. Product recalls or serious safety issues could have a significant negative impact ⁸¹. The company is highly dependent on key personnel, and difficulties in attracting and retaining qualified individuals could impede business strategy implementation ⁸². Managing organizational growth may present challenges ⁸³. System failures or cyber-attacks could disrupt operations, lead to data breaches, and incur liabilities ⁸⁴. Product liability lawsuits could result in substantial liabilities and limit commercialization ⁸⁵. The company's German subsidiary and third-party employees are subject to German employment law, which could lead to disputes over employee inventions and compensation ⁸⁶. The results of R&D efforts are uncertain and may not enhance commercial success ⁸⁷. There is substantial doubt about the company's ability to continue as a "going concern" due to a history of operating losses and insufficient current capital resources ⁸⁸. Existing and future indebtedness could adversely affect business operations and financial flexibility ⁸⁹. Delays or termination of clinical trials for Ameluz indication expansion would result in unplanned expenses and adversely impact commercial prospects ⁹⁰. Products may pose safety issues or adverse events that delay or prevent regulatory approval or limit commercial profiles ⁹¹. The lengthy and unpredictable FDA approval processes for additional indications could substantially harm the business if approvals are not obtained timely or at all ⁹². Reliance on third parties for clinical trials carries risks if they fail to perform contractual duties or meet deadlines ⁹³. Failure to maintain an effective system of internal controls could impair financial reporting and investor confidence ⁹⁴. The company's share price may be volatile, and failure to maintain Nasdaq listing standards could result in delisting ⁹⁵. The exercise or conversion of outstanding warrants and convertible preferred stock could result in significant dilution to stockholders ⁹⁶.

Management's overall tone emphasizes a strategic focus on improving patient outcomes in the non-melanoma space through the adoption and use of their products, particularly Ameluz PDT ⁹⁷. Key strategic priorities include expanding U.S. sales of Ameluz for actinic keratosis (AK) and positioning it as the standard of care by acquiring new customers and growing the therapy in the current customer base ⁹⁸. A second priority is leveraging the potential for future approvals and label extensions of Ameluz in the U.S. market, with the company having taken over responsibility for certain ongoing clinical trials since June 1, 2024, to manage costs and oversee trial efficiency ⁹⁹. The third strategic priority involves opportunistically adding complementary products or services to the portfolio through acquisitions or licensing of intellectual property to further leverage their commercial infrastructure and customer relationships ¹⁰⁰. Management explicitly stated that the Strategic Transaction, which finalized the acquisition of all U.S. rights to Ameluz and RhodoLED, is expected to reduce overall costs and accelerate the company's timeframe to reach break-even ¹⁰¹. The company plans to address its going concern issues by continuing to expand Ameluz commercialization in the U.S. while controlling expenses, expecting an additional $1.0 million in milestone payments from the Xepi asset sale, and, if necessary, securing additional capital through equity or debt financings ¹⁰².